Using Kenta’s proprietary hybridoma cell line, Rentschler will develop a manufacturing process for the former’s KBSA301 antibody using, for the first time, single-use bioreactor technology.
Nikolaus Rentschler, chief executive officer of Rentschler Biotechnologie, said: “We are excited to work with Kenta on the clinical development of this promising product. It will be a pleasure to complement Kenta’s knowledge with our experience in manufacturing biological drugs and we are looking forward to a successful partnership.”
Violetta Georgescu-Kyburz, chief executive officer of Kenta, said: “Rentschler manufactures biopharmaceuticals to exacting standards and will be a key partner for us as we progress the development of a much-needed treatment.”
KBSA301 is a fully-human IgG antibody designed to treat infections caused by MRSA, a type of bacteria that can become resistant to certain antibiotics, including methicillin, oxacillin, penicillin and amoxicillin. KBSA301 has shown in several preclinical animal models that the antibody is very effective in treating severe S aureus infections.